ruxolitinib (Jakavi)

following a full submission assessed under the end of life and orphan equivalent medicine process:

ruxolitinib (Jakavi®) is accepted for use within NHSScotland.

Indication under review: for the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.

In a randomised, open-label, phase III study, ruxolitinib treatment resulted in a statistically significant improvement in overall response rate compared with best available therapy in patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.